RxDoctor Payments Data

Jose Aristizabal, MD

Pulmonary Disease · Decatur, GANPI 1053385930

Payments from drug & device makers

$18,385in general payments, 2019–2025

Across 951 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • Olympus Corporation Of The Americas$1K
  • Actelion Pharmaceuticals US, Inc.$878
  • Jazz Pharmaceuticals Inc.$839
  • plus $9K from 50 others

What the payments were for

  • Travel & lodging$9355%
  • Food & beverage$17,08693%
  • Education$3642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,385 in reported general payments places this provider in the 75th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$83,085
Medicare patients
255
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter412$389,852
AdempasRiociguat18$236,674
OfevNintedanib Esylate17$223,411
Orenitram ErTreprostinil Diolamine13$169,533
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr233$137,488
Breztri AerosphereBudesonide/Glycopyr/Formoterol64$52,872
Breo ElliptaFluticasone/Vilanterol84$50,517
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$40,592
EliquisApixaban29$28,296
Spiriva RespimatTiotropium Bromide32$22,522
SymbicortBudesonide/Formoterol Fumarate39$15,042
Bosentan12$14,934
Advair HfaFluticasone Propion/Salmeterol23$9,643
Arnuity ElliptaFluticasone Furoate12$4,838
Albuterol Sulfate HfaAlbuterol Sulfate188$4,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$2,647$582,695741 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$2,088$286,52597 claims
BayerAdempas$60$236,67418 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,223$67,914103 claims
PfizerEliquis$70$28,29629 claims
Actelion Pharmaceuticals US, Inc.Bosentan$878$14,93412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →